Bioanalytical Mass Spectrometry Facility, Mark Wainwright Analytical Centre, The University of New South Wales, Sydney, Australia.
J Gastroenterol Hepatol. 2013 Jul;28(7):1076-86. doi: 10.1111/jgh.12193.
Genome-wide studies in inflammatory bowel disease (IBD) have allowed us to understand Crohn's disease and ulcerative colitis as forms of related autoinflammatory disorders that arise from a multitude of pathogenic origins. Proteomics and metabolomics are the offspring of genomics that possess unprecedented possibilities to characterize unknown pathogenic pathways. It has been about a decade since proteomics was first applied to IBD, and 5 years for metabolomics. These techniques have yielded novel and potentially important findings, but turning these results into beneficial patient outcomes remains challenging. This review recounts the history and context of clinical IBD developments before and after proteomics and metabolomics IBD in this field, discusses the challenges in consolidating high complexity data with physiological understanding, and provides an outlook on the emerging principles that will help interface the bioanalytical laboratory with IBD prognosis.
全基因组研究表明，炎症性肠病（IBD）是多种致病根源引起的相关自身炎症性疾病，其中包括克罗恩病和溃疡性结肠炎。蛋白质组学和代谢组学是基因组学的分支，为未知的致病途径的特征提供了前所未有的可能。从首次将蛋白质组学应用于 IBD 到现在已经有大约十年的时间，代谢组学则是五年前开始应用于 IBD。这些技术已经产生了新的、潜在重要的发现，但将这些结果转化为有益的患者结果仍然具有挑战性。本综述回顾了蛋白质组学和代谢组学应用于 IBD 之前和之后，该领域的临床 IBD 发展的历史和背景，讨论了将高复杂性数据与生理学理解相结合的挑战，并展望了新兴的原则，这些原则将有助于将生物分析实验室与 IBD 预后联系起来。
